Table 2. Metabolism under the control of Per2.
| Carbohydrate Metabolism ‘ WT genes’ I30 | Fold change [Exp. Value] |
| surfactant protein C | 6.63 |
| protein phosphatase 1, regulatory subunit 3C | 2.383 |
| uncoupling protein 3 | −3.14 |
| Lipid Metabolism ‘WT genes’ I30 | |
| surfactant protein C | 6.63 |
| activating transcription factor 3 | 3.489 |
| protein phosphatase 1, regulatory subunit 3C | 2.383 |
| enoyl-CoA, hydratase/3-hydroxyacyl CoA dehydrogenase | −2.916 |
| uncoupling protein 3 | −3.14 |
| Carbohydrate Metabolism ‘ WT genes’ IP0 | |
| nuclear receptor subfamily 4, group A, member 1 | 3.017 |
| nuclear receptor subfamily 4, group A, member 2 | 2.727 |
| protein phosphatase 1, regulatory subunit 3C | 2.514 |
| protein phosphatase 1, regulatory subunit 15A | 2.303 |
| Lipid Metabolism ‘WT genes’ IP0 | |
| FBJ murine osteosarcoma viral oncogene homolog | 6.122 |
| nuclear receptor subfamily 4, group A, member 1 | 3.017 |
| nuclear receptor subfamily 4, group A, member 2 | 2.727 |
| heat shock 70kDa protein 8 | 2.552 |
| natriuretic peptide B | 2.348 |
| protein phosphatase 1, regulatory subunit 3C | 2.514 |
| enoyl-CoA, hydratase/3-hydroxyacyl CoA dehydrogenase | −2.072 |
| Carbohydrate Metabolism ‘ WT genes’ I30R60 | |
| interleukin 1, beta | 3.556 |
| nuclear receptor subfamily 4, group A, member 3 | 3.354 |
| neurotensin | 3.128 |
| nuclear receptor subfamily 4, group A, member 2 | 2.742 |
| nuclear receptor subfamily 4, group A, member 1 | 2.576 |
| solute carrier family 5 (sodium/myo-inositol cotransporter), member 3 | 2.492 |
| connective tissue growth factor | 2.112 |
| Lipid Metabolism ‘WT genes’ I30R60 | |
| prostaglandin-endoperoxide synthase 2 | 4.15 |
| nuclear receptor subfamily 4, group A, member 3 | 3.354 |
| nuclear receptor subfamily 4, group A, member 2 | 2.742 |
| enoyl-CoA, hydratase/3-hydroxyacyl CoA dehydrogenase | −2.012 |
Shown are the top metabolic genes accounting for the identification of carbohydrate or fatty acid metabolism as top networks or canonical pathways when analyzing genes that are only regulated in wildtype but not in Per2−/− mice using different ischemia and reperfusion protocols. WT = wildtype, I30 = 30 minutes of ischemia, IP0 = ischemic preconditioning (4 times 5 minutes of ischemia and reperfusion), I30R60 = 30 minutes of ischemia and 60 minutes of reperfusion. Given are the expression values (fold change) obtained by Ingenuity pathway analysis. Bold genes appear in more than one treatment group, indicating a robust differentially regulated gene.